摘要
升高的低密度脂蛋白胆固醇(LDL-C)水平是动脉粥样硬化性心血管疾病的主要危险因素。低密度脂蛋白受体在LDL-C的清除过程中发挥重要作用,而前蛋白转化酶枯草溶菌素9(PCSK9)能够通过与低密度脂蛋白受体的特异性结合影响LDLC的清除,因而,PCSK9单克隆抗体可以通过抑制PCSK9的活性,使血液中的LDL-C水平降低。目前PCSK9单克隆抗体已经完成Ⅰ期、Ⅱ期临床研究,Ⅲ期临床研究正在进行中,据近期报道Ⅲ期临床研究也取得了重大进展。
Elevated low-density lipoprotein cholesterol（ LDL-C） is a major risk factor for atherosclerotic cardiovascular disease. Lowdensity lipoprotein receptor（ LDL-R） plays an important role in the clearance of LDL-C,while the proprotein convertase subtilisin / kexintype 9（ PCSK9） can influence the clearance of LDL-C by specific binding with LDL-R,therefore,PCSK9 monoclonal antibody could reduce the level of LDL-C via inhibiting the activity of PCSK9. Now the phase Ⅰ and Ⅱ clinical studies of PCSK9 monoclonal antibody have completed,and according to recent reports,phase Ⅲ clinical studies have also made significant progress.
出处
《心血管病学进展》
CAS
2015年第2期154-158,共5页
Advances in Cardiovascular Diseases
基金
上海申康适宜技术推广项目(SHDC12012210)
宝山区科委项目(12-E-63)
